Creatine boosted cancer-fighting immune cells in mice

Scout Impact

Dendritic cells inside tumors switch on the creatine transporter (CrT/Slc6a8) and depend on that fuel to activate cancer-killing T cells. Blocking uptake weakened the response in mice, creatine supplementation slowed melanoma growth, and human dendritic cells in culture showed the same boost — the mechanism is energy, with creatine preserving the ATP these cells burn through. This is preclinical: mice and cells, not cancer patients. It changes no Scout product score; it is context on a supplement millions already take.

Key Findings

• Intratumoral dendritic cells upregulate the creatine transporter (CrT; Slc6a8), pulling in creatine as an energy store.
• Dendritic cells from CrT knockout mice showed impaired activation and a reduced ability to trigger antigen-specific CD8 T cell responses.
• Creatine supplementation enhanced dendritic cell activation in vitro and in vivo, and suppressed tumor growth in a syngeneic melanoma model.
• Human monocyte-derived dendritic cells — the type used in dendritic-cell cancer vaccines — showed the same boost in activation and T-cell stimulation.
• Mechanism: CrT preserves intracellular ATP, sustaining the energy-dependent inflammatory signaling that activation requires.

Limitations

• Conducted in mice and in cultured human cells — not in cancer patients. No clinical trial has tested creatine as a cancer therapy, and the authors state no dietary or medical recommendations should be drawn from this work.
• Tumor results come from a single syngeneic melanoma model, so they may not generalize to other cancers; anyone in cancer treatment should consult their doctor before adding a supplement.